Development Stage Preclinical
Preclinical
Phase I
Phase II
Phase III
Approved
Preclinical: Animal & In-vitro studies
Thymosin Alpha-1
Also known as: Thymalfasin, Zadaxin
Last updated: 1/22/2026 Last reviewed: 1/22/2026
At a Glance
Thymosin alpha-1 (often referred to as thymalfasin) is studied as an immunomodulatory peptide in a variety of clinical and preclinical contexts.
⚠️ Evidence varies: This page summarizes research only and does not provide medical advice or dosing recommendations.
Mechanism of Action (High Level)
Reported effects involve immune signaling and innate/adaptive responses, but mechanisms and clinical relevance depend heavily on indication and study design.
Evidence Summary
Low Confidence Review ≤3 YearsReview literature discusses thymosin alpha-1’s proposed mechanisms and applications in viral infectious diseases. [PMID: 37110771]
Safety & Unknowns (High Level)
- Safety depends on indication, co-therapies, and study context; consult primary sources and systematic reviews.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved (thymalfasin has approval in some other countries) |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Key Studies
| Year | Type | Topic | Citation |
|---|---|---|---|
| 2023 | Review | Mechanisms and clinical application in viral infectious diseases | [PMID: 37110771] |
📚 See linked items in the Literature section.